Clinical Advisory Board
Daniel D. Von Hoff (Chair), MD, F.A.C.P., University of Arizona, is currently Director of the University of Arizona Health Sciences Center's Cancer Therapeutics Program and Professor of Medicine, Molecular Biology and Pathology at the Arizona College of Medicine. In addition, he serves as Executive Vice President, Director of Translational Drug Development and head of Pancreatic Cancer Research at TGen. He is a previous President of the American Association for Cancer Research and Director of the Arizona Cancer Institute. He is also a founder of ILEX Oncology and Editor-in-Chief of Molecular Cancer Therapeutics.
Herbert M. "Bob" Pinedo (Board Rep.), MD, PhD is past president of ESMO (European Society for Medical Oncology) and of the VUMC Cancer Center, Amsterdam. Dr. Pinedo is an internationally renowned leader in translational cancer drug development. He was a former board member of EORTC and the Dutch Cancer Society and is currently an advisor to major pharmaceutical companies and is on the BOD of OSI Pharmaceuticals.
James Abbruzzese, M.D. Anderson Cancer Center, is currently Chief of Gastrointestinal Oncology at M.D. Anderson Cancer Center. He is an internationally renowned expert in colorectal, pancreatic and liver cancers, experimental therapeutics for cancer and has been Principal Investigator on virotherapy clinical trials.
Lawrence Shulman, MD, Dana-Farber Cancer Institute, is currently Chief Medical Officer and Senior Vice President for Medical Affairs at the Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. He previously served as clinical director of Hematology-Oncology at Brigham and Women's Hospital, Harvard Medical School. He received his M.D. from Harvard Medical School and trained in hematology-oncology at Harvard (Beth Israel Hospital).
John Crowley, PhD, Cancer Research And Biostatistics (CRAB), is Chief Executive Officer of CRAB, and is Professor of Biostatistics at Fred Hutchinson Cancer Research Center and the University of Washington. He has 30 years of experience in Biostatistics and cancer clinical trials. Under Dr. Crowley's leadership, CRAB serves as the Statistical Center for the Southwest Oncology Group, a federally sponsored clinical research consortium comprised of thousands of cancer centers and investigators across the nation. Dr. Crowley oversees the study design, protocol development, data management, quality control, data analysis, and statistical research of more than 100 active multi-site clinical cancer trials. Dr. Crowley manages a staff of 75 high-level statisticians, data coordinators and other professionals dedicated to conquering cancer through large-scale clinical trials. He received his PhD degree in Biomathematics from the University of Washington, and was a Postdoctoral Fellow at Stanford University.
Scientific Advisory Board
Geoffrey L. Smith (Chair), FRS, FMedSci, FIBiol, is a Wellcome Trust Principal Research Fellow, Chair of Dept in the Division of Investigative Science, and head of the Department of Virology at the Faculty of Medicine at Imperial College, London, UK. In recognition of his major contributions to the understanding of poxviruses, he was awarded the 2005 Feldburg Foundation Prize.
David L. Bartlett, MD, is currently The Bernard Fisher Professor of Surgery and Chief of Surgical Oncology at the University of Pittsburgh. Dr. Bartlett has helped develop techniques for the delivery of hyperthermia and chemotherapy directly to the peritoneal cavity as a recirculating perfusion. He has over fifty publications in the field of oncolytic pox viruses, pox virus engineering, clinical oncology and genetic therapy.
Mark J. Federspiel, PhD, Mayo Clinic Rochester, is a tenured faculty member of the Mayo Clinic. He helped develop Mayo Clinic Viral Vector Production Laboratory to provide large scale virus production and the capability to produce clinical grade gene and virus therapy. He has an extensive expertise in the development and use of retroviral vectors, virological assays and animal models.
Stephen J. Russell, MD, PhD, Mayo Clinic, is the Director of Molecular Medicine Program at Mayo Clinic, which is one of the leading groups in virotherapy. Dr. Russell previously held a faculty position in Hematology at Cambridge University and was co-founder of Cambridge Genetics.
Louis Siminovitch, PhD, DSc, CC, FRSC, FRS is a pioneer in human genetics and has helped establish internationally renowned programs exploring the roots of cancer in Ontario, Canada. Dr. Siminovitch has received a long list of scientific and other awards including many honorary degrees, among which are the Flavelle Gold Medal of the Royal Society of Canada (1978), the Gairdner Foundation Wightman Award (1981). He has been made both an Officer and Companion of the Order of Canada (1980, 1989), and was inducted into the Canadian Medical Hall of Fame in 1997.